AstraZeneca Group plc | TalkMarkets | Page 1
No data available
No data available

People who follow this stock (92)

Latest Posts

About This Stock More About This Stock
Pharma Stock Roundup: Novo Nordisk's New Obesity Pill Data, Roche, AstraZeneca's Pipeline Updates
Article By: Zacks Investment Research
Saturday, March 9, 2024 1:40 PM EDT
This week, data from Novo Nordisk’s early-stage study on a new weight loss pill called amycretin showed that it could be more effective than Wegovy. Meanwhile, the FDA approved Johnson & Johnson's lung cancer medicine, Rybrevant, for first-line use.
In this article: AZN, JNJ, NVO, RHHBY, ALNY Also: MRK, PFE
Week In Review: Mabwell Sells Ex-China Rights To Rare Disease Therapy In $412 Million Deal
Article By: ChinaBio® Today
Saturday, March 2, 2024 2:00 PM EDT
Mabwell, a Shanghai-San Diego biotech, sold ex-China rights for 9MW3011 to Disc Medicine of Watertown, MA in a deal worth up to $412 million. Meanwhile, AstraZeneca has returned most of the global rights for Roxadustat to FibroGen.
In this article: AZN, TEVA, FGEN, KZR, IVBXF, IRON
Week In Review: LianBio To Close Operations; Will Pay $528 Million To Shareholders
Article By: ChinaBio® Today
Saturday, February 17, 2024 2:20 PM EDT
LianBio, a Princeton-Shanghai biotech, has decided to call it quits. LianBio plans to stop all of its operations by the end of 2024, and it will distribute a $4.80 dividend/share ($528 million) to its shareholders.
In this article: AZN, CASI, CHGCY, LIAN
Week In Review: Lee’s Pharma Signs $138 Million Agreement For China Rights To Heart Failure Therapy
Article By: ChinaBio® Today
Saturday, January 20, 2024 2:40 PM EDT
Lee’s Pharma acquired China rights to a heart failure therapy from Windtree Therapeutics. Meanwhile, AstraZeneca signed an investment cooperation agreement with the Taizhou National Medical High-tech Development Zone to build a new production line.
In this article: AZN, WINT, CRTHF, ADAG Also: MRK
Week In Review: $1.7 Billion Collaboration Between Elpiscience And Astellas Is Final 2023 Deal
Article By: ChinaBio® Today
Sunday, December 31, 2023 11:00 AM EDT
Shanghai’s Elpiscience Biopharma has formed a $1.7 billion collaboration with Japan’s Astellas Pharma to develop a novel bispecific macrophage engager, ES019, along with an unspecified program. Initially, Elpiscience will receive up to $37 million.
In this article: AZN, ALPMY, GRCL, LIAN, IVBXF

Latest Tweets for $AZN

No tweets yet!



Cruising For A Bruising
The Good Doctor 2/20/2024 1:00:52 AM

Interesting read, though this doesn't say much about $AZN which I'd like to hear more about.  That has not risen like the Mag 7. Generally when big tech falls, $AZN goes up. It's a great hedge. This article is a good read, but is also just ifs, buts and maybes.  I would like to hear your take more definitively. Thanks.

AstraZeneca Q4 Earnings Beat, Sales Hurt By COVID Jab
Frank J. Williams 2/9/2023 4:07:56 PM

AstraZeneca's vaccine was not crated to generate a profit therefore margins will improve. It's good news...not bad! Bullish on $AZN.

Astrazeneca Vs. Novavax: Which Vaccine Stock Is A Better Buy?
Karen Klein 2/14/2021 4:58:18 AM

$AZN looks like the best option since it's easy to transport and so cheap to produce. But it sounds like it's not particularly effective against the new strains.

VistaGen Is Prepared For 2021 Fueled By Recent Analyst Upgrades And Large Institutional Buyers
Terrence Howard 1/11/2021 6:59:49 AM

Good article, thanks. Totally unrelated but what do you think about $AZN? I know Pfizer and Moderna have the head start on the vaccine, but it sounds like AZN's drug will be almost as effective at 90% efficacy (if they can replicate their initial test where they accidentally gave a quarter of the participants a 1/2 dose). And at $2 per vial instead of $200, I would think it will be the drug of choice for populous, yet poor nations like India, and Africa. Plus there will be no need for specialized freezers.

AstraZeneca Vaccine Only 62% Effective; Impact On Elderly Unclear As More Data Needed
Craig Newman 12/8/2020 5:20:20 PM

$AZN has not even filed or talked about filing in US or UK to my knowledge. They are hoping to get India to bite first via Serum Institute. Their trial was so F'd UP the most value to FDA is in denying to prove that other approvals are REAL..

Market Briefing For Thursday, September 10
Adam Reynolds 11/29/2020 5:39:15 PM

What's your take on the latest news on $AZN?

Good Day For Bad News
Ayelet Wolf 11/29/2020 5:37:45 PM

I thought this as well. 90% efficacy is almost as good as the 95% efficacy of the #Pfizer and #Moderna vaccines. But is a much cheaper alternative. Bullish on $AZN

Market Briefing For Thursday, September 10
Atif Ozcelik 9/10/2020 10:37:10 AM

Comments on the major vaccine producers are very useful; thank for the information on $SRNE, $AZN.

When Profits and Politics Drive Science: Rushing a Vaccine to Market for a Vanishing Virus
Adam Reynolds 6/4/2020 5:09:08 PM

Yes and Fauci and other experts said corona is likely here to stay. We will probably have seasonal outbreaks every year. There will be plenty of time to profit from a vaccine. Bullish on $AZN, $MRNA.

1 to 9 of 9 comments